• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Iranian Journal of Pharmaceutical Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 18 (2019)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 17 (2018)
Volume Volume 16 (2017)
Volume Volume 15 (2016)
Volume Volume 14 (2015)
Volume Volume 13 (2014)
Volume Volume 12 (2013)
Volume Volume 11 (2012)
Volume Volume 10 (2011)
Volume Volume 9 (2010)
Volume Volume 8 (2009)
Volume Volume 7 (2008)
Volume Volume 6 (2007)
Volume Volume 5 (2006)
Volume Volume 4 (2005)
Volume Volume 3 (2004)
Volume Volume 2 (2003)
Volume Volume 1 (2002)
Jamhiri, M., Safi Dahej, F., Astani, A., Hejazian, S., Hafizibarjin, Z., Ghobadi, M., Moradi, A., Khoradmehr, A., Safari, F. (2019). Carvacrol Ameliorates Pathological Cardiac Hypertrophy in Both In-vivo and In-vitro Models. Iranian Journal of Pharmaceutical Research, 18(3), 1380-1394. doi: 10.22037/ijpr.2019.1100766
Mohabbat Jamhiri; Farzan Safi Dahej; Akram Astani; Seyed Hasan Hejazian; Zeinab Hafizibarjin; Mojtaba Ghobadi; Ali Moradi; Arezu Khoradmehr; Fatemeh Safari. "Carvacrol Ameliorates Pathological Cardiac Hypertrophy in Both In-vivo and In-vitro Models". Iranian Journal of Pharmaceutical Research, 18, 3, 2019, 1380-1394. doi: 10.22037/ijpr.2019.1100766
Jamhiri, M., Safi Dahej, F., Astani, A., Hejazian, S., Hafizibarjin, Z., Ghobadi, M., Moradi, A., Khoradmehr, A., Safari, F. (2019). 'Carvacrol Ameliorates Pathological Cardiac Hypertrophy in Both In-vivo and In-vitro Models', Iranian Journal of Pharmaceutical Research, 18(3), pp. 1380-1394. doi: 10.22037/ijpr.2019.1100766
Jamhiri, M., Safi Dahej, F., Astani, A., Hejazian, S., Hafizibarjin, Z., Ghobadi, M., Moradi, A., Khoradmehr, A., Safari, F. Carvacrol Ameliorates Pathological Cardiac Hypertrophy in Both In-vivo and In-vitro Models. Iranian Journal of Pharmaceutical Research, 2019; 18(3): 1380-1394. doi: 10.22037/ijpr.2019.1100766

Carvacrol Ameliorates Pathological Cardiac Hypertrophy in Both In-vivo and In-vitro Models

Article 22, Volume 18, Issue 3, Summer 2019, Page 1380-1394  XML PDF (2.58 MB)
Document Type: Research article
DOI: 10.22037/ijpr.2019.1100766
Authors
Mohabbat Jamhiri1; Farzan Safi Dahej1; Akram Astani2; Seyed Hasan Hejazian1; Zeinab Hafizibarjin1; Mojtaba Ghobadi1; Ali Moradi3; Arezu Khoradmehr4; Fatemeh Safari email orcid 1, 5
1Department of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
2Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
3Department of Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
4Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
5Biotechnology Research Center, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract
Hypertension-induced left ventricular hypertrophy is the most important risk factor for heart failure. This study aimed at investigating the effects of monoterpenoid phenol, carvacrol, on myocardial hypertrophy using both in-vivo and in-vitro models. Male Wistar rats were divided into the control (Ctl), un-treated hypertrophy (H), and carvacrol-treated hypertrophy groups (25, 50 and 75 mg/kg/day, Car+H). In the hypertrophy groups animals underwent abdominal aorta banding. Blood pressure (BP) was recorded via carotid artery cannulation. TUNEL assay and Masson’s trichrome staining were used to assess apoptosis and fibrosis, respectively. The 2-2-diphenyl 1-picril-hydrasil)DPPH( radical scavenging activityand malondialdehyde (MDA) level were estimated by biochemical tests. In in-vitro study H9c2 cardiomyoblasts were treated with angiotensin II (Ang II) to promote hypertrophy. Cell size was measured using crystal violet staining. Gene expression was evaluated by real-timeRT-PCR technique. In the carvacrol-treated rats BP, heart rate, and heart weight to the body weight ratio were significantly decreased. In-vitro study showed that H9c2 cell size was significantly reduced compared to Ang II-treated cells. Both in-vivo and in-vitro studies demonstrated that carvacroldecreased atrial natriuretic peptide )ANP( mRNA level significantly (vs. H groups). The number of apoptotic cells increased in Hgroup, while it was decreased in the Car50+H and Car75+H. In Car+H groups, in comparison with H group, the serum concentration of MDA was decreased and DPPHwas increased significantly. Our findings demonstrated that carvacrol decreases hypertrophy markers in in-vivo and in-vitro models of hypertrophy.
Keywords
Cardiac hypertrophy; Carvacrol; Rat; H9c2 cells; Blood pressure; Antioxidant; Apoptosis
Main Subjects
Pharmacognosy
Statistics
Article View: 206
PDF Download: 158
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Statistics

Journal Management System. Designed by sinaweb.